Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-03-16
IRADIMED CORPORATION to Participate at the 38th Annual Roth ConferenceIRMD — IRadimed Corp
NASDAQ · Health Care · Health Care
$89.18-7.33%Market cap1.23B
- Latest Close
- $89.18
- 30-Day Move
- -7.3%
- Market Cap
- $1.2B
- Shares Outstanding
- 12,780,000
- P/E Ratio
- 54.72
- P/B Ratio
- 13.08
Analyst consensus: Buy · 8 analysts
NASDAQ:IRMDHealth Care / Health CareDelayed public snapshot
IRadimed Corp
A read-only Alphactor snapshot forIRadimed Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$89.18
30-Day Move
-7.3%
Market Cap
$1.2B
Shares Outstanding
12,780,000
P/E Ratio
54.72
P/B Ratio
13.08
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$89.18
-7.3%last 90 delayed daily bars
Market cap$1.2B
90D High
$107.90
90D Low
$89.18
Avg Volume
81,225
What stands out
Gross margin is running at 76.8%, which gives a quick read on operating quality before you open the full model.
Net margin is 26.8%, useful for comparing IRMD against peers in Health Care.
IRMD is down 7.3% over the last 30 trading days shown on this page.
Latest operating income is $7M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$30.74
Rule of 40
34.2%
Dark Pool Short %
52.4%
Fundamentals snapshot
Latest Close
$89.18
30-Day Move
-7.3%
Market Cap
$1.2B
Shares Outstanding
12,780,000
P/E Ratio
54.72
P/B Ratio
13.08
ROE
23.8%
ROA
20.7%
Gross Margin
76.8%
Operating Margin
31.2%
Net Margin
26.8%
Debt / Equity
0
Current Ratio
7.98
Dividend Yield
72.9%
Latest Revenue
$23M
Financial statement snapshot
Revenue
$23M
Gross Profit
$17M
Operating Income
$7M
Net Income
$6M
Gross Margin
7675.0%
Net Margin
2682.0%
Current Ratio
7.98
Debt / Equity
0.00
Valuation snapshot
Fair Value
$30.74
Upside / Downside
-65.5%
Signal
Overvalued
Implied Growth
24.9%
DCF
$35.10
EPV
$20.34
EV/Rev
$36.79
Growth Assumption
16.3%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
$17M
Valuation spread
Current Price
$89.18
Composite Fair Value
$30.74
DCF
$35.10
EPV
$20.34
EV/Rev
$36.79
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Quality snapshot
Altman Z
55.30
Safe
Piotroski
7
Strong (7-9)
Cash Conversion
1.11x
Rule of 40
34.2%
Acceptable
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $53M | $16M | $13M | $8M |
| 2023-12-31 | $66M | $20M | $17M | $5M |
| 2024-12-31 | $73M | $22M | $19M | $17M |
| 2025-12-31 | $84M | $26M | $22M | $17M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico', homepage_url='https://www.fool.com/', logo_url='https://s3.massive.com/public/assets/news/logos/themotleyfool.svg', name='The Motley Fool')•2026-02-10
Why Iradimed Stock Soared TodayPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2024-11-18
Baker Hughes Digital Transformation Strategy and Innovation Programs 2024Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2024-11-14
Well Intervention Market to Drive Growth at USD 12.14 Billion by 2031 | SkyQuest TechnologyPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2024-06-07
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global MarketAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$14M
Buys
0
Sells
71
Buy Value
$0
Sell Value
$14M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-14 | Susi Roger E. | Sell | 393 | $94.55 |
| 2026-04-14 | Susi Roger E. | Sell | 2,107 | $93.71 |
| 2026-04-13 | Susi Roger E. | Sell | 589 | $93.45 |
| 2026-04-13 | Susi Roger E. | Sell | 2,564 | $92.79 |
| 2026-04-13 | Susi Roger E. | Sell | 1,847 | $91.84 |
| 2026-04-07 | Susi Roger E. | Sell | 982 | $95.58 |
| 2026-04-07 | Susi Roger E. | Sell | 1,518 | $94.36 |
| 2026-04-06 | Susi Roger E. | Sell | 569 | $96.78 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 259,566 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 198,981 | 0.02% | 2026-02-28 |
| Virtus Equity Trust-Virtus KAR Small-Cap Growth Fund | 139,503 | 0.01% | 2025-12-31 |
| JNL Series Trust-JNL Multi-Manager Small Cap Growth Fund | 96,795 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 87,008 | 0.01% | 2025-12-31 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 82,460 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 78,589 | 0.01% | 2026-01-31 |
| CALAMOS INVESTMENT TRUST/IL-Calamos Timpani Small Cap Growth Fund | 71,620 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
D.E. Shaw
Filed 2026-02-17
--
--
Vanguard Group
Filed 2026-01-29
$54M
-1.1%
Renaissance Technologies
Filed 2026-02-12
$44M
-6.6%
BlackRock
Filed 2024-08-13
$36M
--
Geode Capital Management
Filed 2026-02-09
$25M
-1.6%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.13
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
8
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.